Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Singapore / NCT06044441
Recruiting Not applicable

Evaluation and Implementation Preparation of a Proactive Palliative Care Model (ENABLE-SG)

NCT06044441 · tracked via the Priya Life Science Singapore tracker
Phase
Not applicable
Started
2023-12-26
Last updated
2026-04-30

Condition(s) studied

Neoplasms

Investigational drug(s) / intervention(s)

ENABLE-SG modelWait-list control

ENABLE-SG model: Patients and caregivers will receive individual structured psycho-educational sessions with a health coach. These sessions will be primarily delivered over the phone. Patient and caregiver dyads will have different health coaches. Patients will have six sessions on the topics of maintaining positivity, self-care, coping with stress, managing symptoms, exploring what matters most, and life review. Caregivers will have four sessions on the topics of maintaining positivity, self-care, coping with stress, and managing symptoms. All sessions will begin with screening for distress using the Distress Thermometer and Problem List culturally adapted from the National Comprehensive Cancer Network. From screening results, the health coach can flexibly change the order of the topics to address specific problems. It will take approximately three months to complete all sessions.

Wait-list control: * 6-month wait-list control. Participants will receive the ENABLE-SG model six months after baseline (six sessions for patients and four sessions for caregivers) at an approximately weekly interval. * Interventions: ENABLE-SG model

Study summary

The current interdisciplinary specialist palliative care model focuses on supporting patients with advanced cancer who have complex problems in the last weeks of life. Consequently, palliative care is often provided late and in response to uncontrolled symptoms during crises. Palliative care models should shift from this reactionary illness-stress paradigm to a proactive health-wellness approach that is integrated early in the patient's disease trajectory.

A proactive early palliative care telehealth model, ENABLE (Educate, Nurture, Advise, Before Life Ends), was developed in the U.S. to coach patients with advanced cancers and their family caregivers on how to cope effectively with serious illness. By empowering individuals early before acute distress and symptoms occur, patients and families can better mitigate and avoid crises. Building on positive health outcomes demonstrated by the ENABLE model in the U.S., the study team has successfully pilot-tested a culturally adapted ENABLE-SG model in Singapore. This study seeks to test the effectiveness of this ENABLE-SG model among patients with recently diagnosed advanced cancer and their caregivers while simultaneously collecting data on real-world implementation.

Eligibility

Sex
ALL
Min age
21 Years
Max age
120 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Inclusion criteria for patients: 1. Adult aged 21 and above 2. Within 60 days of being informed of an advanced cancer diagnosis, defined as metastatic or recurrent/ progressive Stage III/IV solid tumour 3. Able to speak English or Chinese 4. Able to provide informed consent 5. Patients will NOT need to have a caregiver willing to participate in the ENABLE-SG programme. * Inclusion criteria for caregivers: 1. Adult aged 21 and above 2. Self-endorsing or identified by the enrolled patient as an unpaid spouse/partner, relative or friend who knows them well and who provides regular support (at least 7 hours a week) due to their cancer and who does not have to live in the same dwelling 3. Caring for a patient with advanced cancer (see definition under patient inclusion criteria above) 4. Able to speak English or Chinese. 5. Able to provide informed consent * Inclusion criteria for healthcare professions: 1. 21 years or older. 2. Approached to participate in the ENABLE-SG study 3. Able to provide informed consent Exclusion Criteria: * Exclusion criteria for patients: 1. Medical record documentation of an active severe mental illness, dementia, active suicidal ideation, uncorrected hearing loss 2. Unable to complete patient-reported outcome measures 3. Has been reviewed by palliative care services in the current model of palliative care. * Exclusion criteria for caregivers: 1. Self-reported severe mental illness, dementia, active suicidal ideation, uncorrected hearing loss 2. Unable to complete caregiver-reported outcomes. * Exclusion criteria for healthcare professional: 1. Healthcare professionals that are not providing care for cancer patients. 2. Unable to complete interviews.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
National Cancer Centre Singapore Singapore Singapore Recruiting

More National Cancer Centre, Singapore trials in Singapore

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06044441 on ClinicalTrials.gov ↗ ← All trials in Singapore